About us Contacts Drug interactions: 390 212
Drug search by name

Eszopiclone and PCE Dispertab

Determining the interaction of Eszopiclone and PCE Dispertab and the possibility of their joint administration.

Check result:
Eszopiclone <> PCE Dispertab
Relevance: 01.10.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Erythromycin may increase the blood levels of eszopiclone. In some cases, this can increase the risk of side effects including daytime drowsiness, motor impairment, amnesia, anxiety, abnormal thinking, hallucinations, behavioral changes, and breathing difficulties (especially if you have a respiratory disorder such as asthma or obstructive sleep apnea). You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Talk to your doctor if you have any questions or concerns. You should avoid the use of alcohol while being treated with eszopiclone. Avoid driving or operating hazardous machinery until you know how the medication affects you, and do not exceed the dosage or frequency of use prescribed by your doctor. Because there may be some residual effects of eszopiclone the day after you take it, it may be advisable to wait at least 12 hours after dosing to drive or operate machinery, even when you may feel fully awake. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR: Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of both zopiclone and its pharmacologically active S(-) enantiomer, eszopiclone. Zopiclone has been shown in vitro to be metabolized by CYP450 3A4 and CYP450 2C8, while eszopiclone is primarily metabolized by CYP450 3A4 and 2E1 via demethylation and oxidation. In 18 healthy subjects, administration of a single 3 mg dose of eszopiclone with the potent CYP450 3A4 inhibitor ketoconazole (400 mg daily for 5 days) increased eszopiclone half-life, peak plasma concentration (Cmax) and systemic exposure (AUC) by 1.3-, 1.4- and 2.2-fold, respectively. In 10 healthy young subjects, itraconazole 200 mg daily given for 4 days increased the Cmax and AUC of a single 7.5 mg dose of zopiclone by 29% and 73%, respectively, and prolonged its half-life by 40%. A case report describes an 86-year-old woman who experienced morning drowsiness during coadministration of zopiclone and nefazodone, a known potent CYP450 3A4 inhibitor. Zopiclone plasma concentrations were measured both during and after withdrawal of nefazodone therapy. Following discontinuation of nefazodone due to lack of therapeutic effect, the plasma concentration of S(-) zopiclone decreased from 107 to 16.9 ng/mL, and that of R(+) zopiclone decreased from 20.6 to 1.45 ng/mL. Limited data are available regarding use with moderate CYP450 3A4 inhibitors. When 10 healthy young volunteers were given a single 7.5 mg dose of zopiclone on the 6th day of treatment with 500 mg erythromycin base three times daily, mean half-life, Cmax and AUC of zopiclone increased by approximately 42%, 38% and 77%, respectively, compared to administration with placebo. Plasma zopiclone concentration increased nearly 4-fold at 0.5 hour postdose and 2-fold at 1 hour postdose, and time to reach peak plasma concentration (Tmax) decreased from 2 hours to 1 hour, suggesting accelerated absorption due to increased gastric emptying induced by erythromycin.

MANAGEMENT: Caution is advised when zopiclone or eszopiclone is coadministered with moderate CYP450 3A4 inhibitors. A dosage reduction may be required if an interaction is suspected. Patients should be advised to avoid driving or operating hazardous machinery until they know how these medications affect them, preferably at least 12 hours after administration of the hypnotic.

References
  • Becquemont L, Mouajjah S, Escaffre O, Beaune P, Funck-Bretano C, Jaillon P "Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism." Drug Metab Dispos 27 (1999): 1068-73
  • "Product Information. Lunesta (eszopiclone)." Sepracor Inc, Marlborough, MA.
  • Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  • Alderman CP, Gebauer MG, Gilbert AL, Condon JT "Possible interaction of zopiclone and nefazodone." Ann Pharmacother 35 (2001): 1378-80
  • "Product Information. Imovane (zopiclone)." Rhone-Poulenc Rorer Canada Inc, Laval, IN.
  • Aranko K, Luurila H, Backman JT, Neuvonen PJ, Olkkola KT "The effect of erythromycin on the pharmacokinetics and pharmacodymanics of zopiclone." Br J Clin Pharmacol 38 (1994): 363-7
  • Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57
Eszopiclone

Generic Name: eszopiclone

Brand name: Lunesta

Synonyms: n.a.

PCE Dispertab

Generic Name: erythromycin

Brand name: EES. Granules, EES-400 Filmtab, EryPed 200, EryPed 400, Ery-Tab, Erythrocin Lactobionate, Erythrocin Stearate Filmtab, PCE Dispertab, E. E. S, EryPed, Erythrocin, Erythromycin Filmtabs, Erythromycin Lactobionate - IV

Synonyms: PCE Dispertab (Oral), PCE, PCE (Oral)

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction